142 related articles for article (PubMed ID: 38036991)
21. Development and validation of a nomogram based on biparametric MRI PI-RADS v2.1 and clinical parameters to avoid unnecessary prostate biopsies.
Wang Y; Wang L; Tang X; Zhang Y; Zhang N; Zhi B; Niu X
BMC Med Imaging; 2023 Aug; 23(1):106. PubMed ID: 37582697
[TBL] [Abstract][Full Text] [Related]
22. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
23. A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter Study.
Mjaess G; Peltier A; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; Nguyen TA; Fournier G; Fiard G; Ploussard G; Roumeguère T; Albisinni S; Diamand R
Eur Urol Focus; 2023 Nov; 9(6):992-999. PubMed ID: 37147167
[TBL] [Abstract][Full Text] [Related]
24. Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.
Truong M; Wang B; Gordetsky JB; Nix JW; Frye TP; Messing EM; Thomas JV; Feng C; Rais-Bahrami S
Cancer; 2018 Jan; 124(2):278-285. PubMed ID: 28976544
[TBL] [Abstract][Full Text] [Related]
25. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
[TBL] [Abstract][Full Text] [Related]
26. Computer-aided diagnosis of prostate cancer using a deep convolutional neural network from multiparametric MRI.
Song Y; Zhang YD; Yan X; Liu H; Zhou M; Hu B; Yang G
J Magn Reson Imaging; 2018 Dec; 48(6):1570-1577. PubMed ID: 29659067
[TBL] [Abstract][Full Text] [Related]
27. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
28. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
Wei CG; Chen T; Zhang YY; Pan P; Dai GC; Yu HC; Yang S; Jiang Z; Tu J; Lu ZH; Shen JK; Zhao WL
Eur J Radiol; 2020 Jun; 127():108977. PubMed ID: 32330776
[TBL] [Abstract][Full Text] [Related]
29. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
30. A Radiomics nomogram for predicting bone metastasis in newly diagnosed prostate cancer patients.
Zhang W; Mao N; Wang Y; Xie H; Duan S; Zhang X; Wang B
Eur J Radiol; 2020 Jul; 128():109020. PubMed ID: 32371181
[TBL] [Abstract][Full Text] [Related]
31. Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.
Lee SM; Liyanage SH; Wulaningsih W; Wolfe K; Carr T; Younis C; Van Hemelrijck M; Popert R; Acher P
Urol Oncol; 2017 Nov; 35(11):664.e11-664.e18. PubMed ID: 28801025
[TBL] [Abstract][Full Text] [Related]
32. Are prostate biopsies necessary for all patients 75years and older?
Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
[TBL] [Abstract][Full Text] [Related]
33. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
[TBL] [Abstract][Full Text] [Related]
34. Establishment and validation of serum lipid-based nomogram for predicting the risk of prostate cancer.
Feng F; Zhong YX; Chen Y; Lin FX; Huang JH; Mai Y; Zhao PP; Wei W; Zhu HC; Xu ZP
BMC Urol; 2023 Jul; 23(1):120. PubMed ID: 37452418
[TBL] [Abstract][Full Text] [Related]
35. The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study.
Chen S; Yang Y; Peng T; Yu X; Deng H; Guo Z
Int J Med Sci; 2020; 17(10):1366-1374. PubMed ID: 32624693
[No Abstract] [Full Text] [Related]
36. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
37. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
[TBL] [Abstract][Full Text] [Related]
38. Interactive Explainable Deep Learning Model Informs Prostate Cancer Diagnosis at MRI.
Hamm CA; Baumgärtner GL; Biessmann F; Beetz NL; Hartenstein A; Savic LJ; Froböse K; Dräger F; Schallenberg S; Rudolph M; Baur ADJ; Hamm B; Haas M; Hofbauer S; Cash H; Penzkofer T
Radiology; 2023 May; 307(4):e222276. PubMed ID: 37039688
[TBL] [Abstract][Full Text] [Related]
39. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
[TBL] [Abstract][Full Text] [Related]
40. Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
Wang J; Wu CJ; Bao ML; Zhang J; Wang XN; Zhang YD
Eur Radiol; 2017 Oct; 27(10):4082-4090. PubMed ID: 28374077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]